Fluicell AB is a Sweden-based company within healthcare industry. It commercializes a product portfolio for processing and studying of individual cells, primarily in the field of drug development. The Companyâ€™s products comprise research tools BioPen and Dynaflow Resolve. Tools enable researchers to study, process and measure drug impact on individual cells. Also, the Company develops bioprinting technology Biopixlar Retina in both two-dimensional (2D) and three-dimensional (3D) options. Biopixlar Retina creates complex tissue-like structures with control over positioning of individual cells.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-13 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
05/10/26	SEK 29.20	-2.67%	920
02/10/26	SEK 30.00	+2.39%	3,431
01/10/26	SEK 29.30	0.00%	1,842
30/09/26	SEK 29.30	-2.66%	3,800
29/09/26	SEK 30.10	+1.01%	857

Delayed Quote Nasdaq Stockholm

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Nasdaq Stockholm 19:00:00 05/10/2026 +03			5-day change	1st Jan Change
29.20 ^SEK	-2.67%		-1.35%	+192.00%

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	40.11M 4M 3.56M 3.32M 3.02M 5.7M 385M 5.74M 15.61M 197M 15.01M 14.69M 636M	P/E 2024	-1.1x	P/E 2025	-1.65x
Enterprise Value	37.85M 3.77M 3.36M 3.13M 2.85M 5.38M 363M 5.41M 14.73M 185M 14.17M 13.86M 600M	EV / Sales 2024	2.04x	EV / Sales 2025	1.91x
Free-Float	70.1%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	FLUI	Delayed
Deutsche Boerse AG	5J90	Delayed
Boerse Muenchen	5J90	Real-time
Börse Stuttgart	5J90	Delayed

09-15	Fluicell: Delayed €0.5m receivable settled	FW
08-28	Fluicell AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-28	Fluicell increases revenue and turns to operating profit	FW
05-08	Fluicell reports sharp revenue surge and swings to profit in the first quarter	FW
05-08	Fluicell Q1 net sales up at SEK 6.1 million	RE
05-08	Fluicell AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Fluicell nominates AstraZeneca executive to Board of Directors	FW
04-30	Committee proposes Niklas Frisk as Fluicell chairman	RE
04-30	Fluicell proposes new Board of Directors	FW
02-20	Fluicell Narrows Operating Loss in Q4, Final Report Confirms	FW
02-20	Fluicell Q4 net sales SEK 3.8 mln	RE
02-20	Fluicell AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Fluicell gets EPO approval for microfluidics patent	RE

Fluicell AB Stock

Stocks

FLUI

SE0023595459

Biotechnology & Medical Research

Valuation: Fluicell AB

Chart: Fluicell AB

Latest news: Fluicell AB

Press Releases: Fluicell AB

Quotes and Performance

Price Extremes

Managers and Directors: Fluicell AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

02/09/25	Fluicell : and Ambusol enter into exclusive global license and development agreement regarding technology for cancer treatment	PU
22/08/25	Fluicell : receives funding from Breakthrough T1D for collaboration with leading medical university to develop tissue-based type 1 diabetes therapeutics	PU
29/09/21	BioStock: Fluicell partners with big pharma for 3-D bioprinting project	AQ
01/07/21	BioStock: 2021 represents beginning of new era for Fluicell	AQ
18/05/21	BioStock: Fluicell dives into regenerative medicine field	AQ

1 day	-2.67%
1 week	-1.35%
Current month	-0.34%
1 month	-6.71%
3 months	-14.12%
6 months	+104.20%
Current year	+192.00%

1 week	29.1	31.4
1 month	28.4	34.1
Current year	7.65	67.2
1 year	7.65	67.2
3 years	7.45	594.3
5 years	7.45	10,780
10 years	7.45	15,330

Manager	Title	Age	Since
Carolina Trkulja CEO	Chief Executive Officer	42	01/01/2023
Gavin Jeffries CTO	Chief Tech/Sci/R&D Officer	46	01/01/2017
Niklas Joakim Wahlberg DFI	Director of Finance/CFO	56	01/07/2023

Director	Title	Age	Since
Daniel T. Chiu BRD	Director/Board Member	54	01/01/2017
Carl Fhager BRD	Director/Board Member	51	01/01/2017
Jan Orwar BRD	Director/Board Member	62	01/01/2015

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FLUICELL AB	-2.67%	-1.35%	+65.91%	-91.69%	4.11M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.88%	+19.75%	+78.35%	57.39B
LONZA GROUP AG	+1.63%	+0.98%	+3.83%	+38.21%	47.64B
REVOLUTION MEDICINES, INC.	+0.50%	+1.32%	+344.62%	+753.25%	44.29B
IQVIA HOLDINGS INC.	+3.05%	-1.58%	+28.78%	+35.46%	42.5B
BEONE MEDICINES AG	+1.00%	+0.22%	+5.17%	+113.80%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.76%	-0.89%	-7.44%	-11.43%	24.34B
Average	+0.91%	-0.39%	+55.06%	+109.11%	39.05B
Weighted average by Cap.	+1.55%	-0.84%	+58.06%	+140.75%

	2024	2025
Net sales	1.86M 185K 165K 154K 140K 264K 17.85M 266K 723K 9.11M 696K 681K 29.49M	6M 598K 533K 497K 453K 854K 57.62M 859K 2.33M 29.41M 2.25M 2.2M 95.21M
Net income	-15.51M -1.55M -1.38M -1.28M -1.17M -2.21M -149M -2.22M -6.03M -76M -5.81M -5.68M -246M	-8.33M -831K -740K -690K -628K -1.18M -79.99M -1.19M -3.24M -40.82M -3.12M -3.05M -132M
Net Debt	-15.92M -1.59M -1.41M -1.32M -1.2M -2.26M -153M -2.28M -6.19M -78.02M -5.96M -5.83M -253M	-2.26M -226K -201K -187K -171K -322K -21.72M -324K -880K -11.08M -847K -828K -35.88M